What is the mechanism behind increased permeation rate of a poorly soluble drug from aqueous dispersions of an amorphous solid dispersion?

Journal of Pharmaceutical Sciences

Volumn 103, Issue 6, 2014, Pages 1779-1786

  Frank, Kerstin J ^a,b,d   Westedt, Ulrich ^c   Rosenblatt, Karin M ^c   Hölig, Peter ^c   Rosenberg, Jörg ^c   Mägerlein, Markus ^c   Fricker, Gert ^b   Brandl, Martin ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c ABBVIE INC   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

amorphous; microparticles; permeability; solid dispersion; solubility; supersaturation

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; INDAZOLE DERIVATIVE; UREA; WATER;

AMORPHOUS SOLID DISPERSION; AQUEOUS SOLUTION; ARTICLE; CRITICAL MICELLE CONCENTRATION; DISPERSION; DRUG PENETRATION; DRUG SOLUBILITY; FIELD FLOW FRACTIONATION; HUMAN; HUMAN CELL; MICELLE; ANALOGS AND DERIVATIVES; CACO 2 CELL LINE; CHEMISTRY; SOLUBILITY;

CACO-2 CELLS; HUMANS; INDAZOLES; SOLUBILITY; UREA; WATER;

EID: 84901261550     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23979     Document Type: Article

References (22)

1. Thayer AM,. 2010. Finding solutions. Chem Eng News 88 (22): 13-18.
2. Bikiaris DN,. 2011. Solid dispersions, part I: Recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs. Expert Opin Drug Deliv 8 (11): 1501-1519.
3. Bikiaris DN,. 2011. Solid dispersions, part II: New strategies in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs. Expert Opin Drug Deliv 8 (12): 1663-1680.
4. Breitenbach J,. 2002. Melt extrusion: From process to drug delivery technology. Eur J Pharm Biopharm 54 (2): 107-117.
5. Ghebremeskel AN, Vemavarapu C, Lodaya M,. 2007. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Stability testing of selected solid dispersions. Pharm Res 23 (8): 1928-1936.
6. Wassvik CM, Holmén AG, Draheim R, Artursson P, Bergström CA,. 2008. Molecular characteristics for solid-state limited solubility. J Med Chem 51 (10): 3035-3039.
7. Kalivoda A, Fischbach M, Kleinebudde P,. 2012. Application of mixtures of polymeric carriers for dissolution enhancement of fenofibrate using hot-melt extrusion. Int J Pharm 429 (1-2): 58-68.
8. Kanzer J, Tho I, Flaten GE, Hölig P, Fricker G, Brandl M,. 2010. In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier. J Pharm Pharmacol 62 (11): 1591-1598.
9. Frank KJ, Westedt U, Rosenblatt KM, Hölig P, Rosenberg J, Mägerlein M, Fricker G, Brandl M,. 2012. The amorphous solid dispersion of the poorly soluble ABT-102 forms nano/microparticulate structures in aqueous medium: Impact on solubility. Int J Nanomed 7: 5757-5768.
10. Kanzer J, Hupfeld S, Vasskog T, Tho I, Hölig P, Mägerlein M, Fricker G, Brandl M,. 2010. In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation. J Pharm Biomed Anal 53: 359-365.
11. Leuner C, Dressman J,. 2009. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50 (1): 47-60.
12. Dahan A, Miller JM, Hoffman A, Amidon GE, Amidon GL,. 2010. The solubility-permeability interplay in using cyclodextrinsas pharmaceutical solubilizers: Mechanistic modeling and application to progesterone. J PharmSci 99 (6): 2739-2749.
13. Fischer SM, Flaten GE, Hagesæther E, Fricker G, Brandl M,. 2011. In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: The influence of nonionic surfactants. J Pharm Pharmacol 63 (8): 1022-1030.
14. Frank KJ, Westedt U, Rosenblatt KM, Hölig P, Rosenberg J, Mägerlein M, Brandl M, Fricker G,. 2012. Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound. Eur J Pharm Sci 47 (1): 16-20.
15. Frank KJ, Rosenblatt KM, Westedt U, Hölig P, Rosenberg J, Mägerlein M, Fricker G, Brandl M,. 2012. Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: True supersaturation vs. apparent solubility enhancement. Int J Pharm 437 (1-2): 288-293.
16. Ilevbare GA, Liu H, Pereira J, Edgar KJ, Taylor LS,. 2013. Influence of additives on the properties of nanodroplets formed in highly supersaturated aqueous solutions of ritonavir. Mol Pharm 10: 3392-3402.
17. Augustijns P, Brewster ME,. 2012. Supersaturating drug delivery systems: Fast is not necessarily good enough. Int J Pharm 101 (1): 7-9.
18. Bevernage J, Brouwers J, Annaert P, Augustijns P,. 2012. Drug precipitation-permeation interplay: Supersaturation in an absorptive environment. Eur J Pharm Biopharm 82 (2): 424-428.
19. Brouwers J, Brewster ME, Augustijns P,. 2009. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability? J Pharm Sci 98 (8): 2549-2572.
20. Sassene PJ, Knopp MM, Hesselkilde JZ, Koradia V, Larsen A, Rades T, Müllertz A,. 2010. Precipitation of a poorly soluble model drug during in vitro lipolysis: Characterization and dissolution of the precipitate. J Pharm Sci 99 (12): 4982-4991.
21. Thomas N, Müllertz A, Graf A, Rades T,. 2012. Influence of lipid composition and drug load on the in vitro performance of self-nanoemulsifying drug delivery systems. J Pharm Sci 101 (5): 1721-1731.
22. Gao P, Shi Y,. 2012. Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs. AAPS J 14 (4): 703-713.